REG - ReNeuron Group plc - Exercise of Share Options and TVR
RNS Number : 0906WReNeuron Group plc12 April 2019
12 April 2019
AIM: RENE
ReNeuron Group plc
Exercise of Share Options and Director's Dealings
Total Voting Rights
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has received notices to exercise options from certain employees and a PDMR of the Company to subscribe for a total of 12,478 new ordinary shares of 1 pence in the Company. The exercise price of the options is £1.00 per share.
On 12 April 2019, Michael Hunt, Chief Financial Officer, exercised options over 3,478 ordinary shares of 1p each in the Company at an exercise price of £1.00 per share. In order to achieve a cashless exercise and pay the relevant taxes, on 12 April 2019 Mr Hunt sold 988 shares at a share price of £2.47 and therefore retains 2,490 shares.
As a result of the exercise and share transaction, Mr Hunt's interest in ordinary shares has increased to 30,036 ordinary shares, representing approximately 0.095% of the Company's issued share capital.
Total voting rights
Following the issue of 12,478 ordinary shares pursuant to the exercise of options described above and exercised through its existing blocklisting arrangements, the Company has 31,658,664 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,658,664 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron
+44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited
+44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP
+44 (0) 20 7496 3000
Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Michael Hunt
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 0.01p
RENE - GB00B0DZML60
b)
Nature of the transaction
Exercise of options over ordinary shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£1.00
3,478
d)
Aggregated information
N/A
e)
Date of the transaction
12 April 2019
f)
Place of the transaction
London Stock Exchange, AIM Market
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Michael Hunt
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 0.01p
RENE - GB00B0DZML60
b)
Nature of the transaction
Sale of ordinary shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£2.47
988
d)
Aggregated information
N/A
e)
Date of the transaction
12 April 2019
f)
Place of the transaction
London Stock Exchange, AIM Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDMSCUUOORKSASAAR
Recent news on ReNeuron
See all newsREG - ReNeuron Group plc - Directorate Change
AnnouncementREG - FTSE Russell - ReNeuron Group
AnnouncementREG - ReNeuron Group plc - Appointment of Administrators
AnnouncementREG - ReNeuron Group plc - Intention to Appoint Administrators
AnnouncementREG - ReNeuron Group plc - Block Listing Review & Total Voting Rights
Announcement